Storz
Executive Summary
American Cyanamid subsidiary receives April 11 reg letter on promotion of Ocuvite, a zinc supplement for eyes. FDA said the company has been promoting the vitamin and mineral product as a prevention or treatment for such conditions as senile macular degeneration, cataracts, night blindness, severe near-sightedness and injuries to the cornea, which constitute drug claims. Storz said that it would meet with FDA at the beginning of the week of May 7 to discuss the agency's objections. In the meantime, the company has stopped all promotion, including journal ads and mailings, for the product, which is manufactured by Lederle. Storz said that Ocuvite promotions target ophthalmologists to encourage them to recommend the product as a preferred zinc supplement to their patients, and that FDA objections probably were directed at a brochure being distributed that specifically mentioned certain eye conditions.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.